vs
Apellis Pharmaceuticals, Inc.（APLS）与COASTAL FINANCIAL CORP（CCB）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是COASTAL FINANCIAL CORP的1.4倍（$199.9M vs $138.0M），COASTAL FINANCIAL CORP同比增速更快（-5.8% vs -5.9%），COASTAL FINANCIAL CORP自由现金流更多（$246.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -3.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
富达国民金融是美国财富500强企业，面向房地产与按揭行业提供产权保险及交割服务。2019年，其产权及房地产业务相关年营收约为84.69亿美元，是行业内具有领先地位的金融服务提供商。
APLS vs CCB — 直观对比
营收规模更大
APLS
是对方的1.4倍
$138.0M
营收增速更快
CCB
高出0.2%
-5.9%
自由现金流更多
CCB
多$260.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $138.0M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 12.4% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -5.8% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.84 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCCB
| Q4 25 | $199.9M | $138.0M | ||
| Q3 25 | $458.6M | $144.7M | ||
| Q2 25 | $178.5M | $119.4M | ||
| Q1 25 | $166.8M | $139.5M | ||
| Q4 24 | $212.5M | $146.5M | ||
| Q3 24 | $196.8M | $151.1M | ||
| Q2 24 | $199.7M | $135.3M | ||
| Q1 24 | $172.3M | $148.4M |
净利润APLSCCB
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $13.6M | ||
| Q2 25 | $-42.2M | $11.0M | ||
| Q1 25 | $-92.2M | $9.7M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $13.5M | ||
| Q2 24 | $-37.7M | $11.6M | ||
| Q1 24 | $-66.4M | $6.8M |
营业利润率APLSCCB
| Q4 25 | -25.6% | 12.4% | ||
| Q3 25 | 48.7% | 12.4% | ||
| Q2 25 | -18.6% | 12.0% | ||
| Q1 25 | -50.0% | 8.4% | ||
| Q4 24 | -12.3% | 11.7% | ||
| Q3 24 | -24.0% | 10.8% | ||
| Q2 24 | -14.7% | 11.1% | ||
| Q1 24 | -36.0% | 5.9% |
净利率APLSCCB
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 9.4% | ||
| Q2 25 | -23.6% | 9.2% | ||
| Q1 25 | -55.3% | 7.0% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 8.9% | ||
| Q2 24 | -18.9% | 8.6% | ||
| Q1 24 | -38.5% | 4.6% |
每股收益（稀释后）APLSCCB
| Q4 25 | $-0.40 | $0.84 | ||
| Q3 25 | $1.67 | $0.88 | ||
| Q2 25 | $-0.33 | $0.71 | ||
| Q1 25 | $-0.74 | $0.63 | ||
| Q4 24 | $-0.30 | $0.95 | ||
| Q3 24 | $-0.46 | $0.97 | ||
| Q2 24 | $-0.30 | $0.84 | ||
| Q1 24 | $-0.54 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $491.0M |
| 总资产 | $1.1B | $4.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCCB
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSCCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCCB
| Q4 25 | $370.1M | $491.0M | ||
| Q3 25 | $401.2M | $475.3M | ||
| Q2 25 | $156.3M | $461.7M | ||
| Q1 25 | $164.2M | $449.9M | ||
| Q4 24 | $228.5M | $438.7M | ||
| Q3 24 | $237.1M | $331.9M | ||
| Q2 24 | $264.3M | $316.7M | ||
| Q1 24 | $266.7M | $303.7M |
总资产APLSCCB
| Q4 25 | $1.1B | $4.7B | ||
| Q3 25 | $1.1B | $4.6B | ||
| Q2 25 | $821.4M | $4.5B | ||
| Q1 25 | $807.3M | $4.3B | ||
| Q4 24 | $885.1M | $4.1B | ||
| Q3 24 | $901.9M | $4.1B | ||
| Q2 24 | $904.5M | $4.0B | ||
| Q1 24 | $831.9M | $3.9B |
负债/权益比APLSCCB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $254.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $246.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 178.3% |
| 资本支出强度资本支出/营收 | 0.1% | 6.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $436.4M |
8季度趋势，按日历期对齐
经营现金流APLSCCB
| Q4 25 | $-14.2M | $254.6M | ||
| Q3 25 | $108.5M | $59.0M | ||
| Q2 25 | $4.4M | $66.0M | ||
| Q1 25 | $-53.4M | $71.7M | ||
| Q4 24 | $19.4M | $259.8M | ||
| Q3 24 | $34.1M | $62.6M | ||
| Q2 24 | $-8.3M | $72.1M | ||
| Q1 24 | $-133.0M | $56.8M |
自由现金流APLSCCB
| Q4 25 | $-14.3M | $246.1M | ||
| Q3 25 | $108.3M | $57.4M | ||
| Q2 25 | $4.4M | $64.0M | ||
| Q1 25 | $-53.4M | $68.9M | ||
| Q4 24 | $19.3M | $249.9M | ||
| Q3 24 | — | $60.2M | ||
| Q2 24 | $-8.4M | $69.5M | ||
| Q1 24 | $-133.3M | $55.0M |
自由现金流率APLSCCB
| Q4 25 | -7.1% | 178.3% | ||
| Q3 25 | 23.6% | 39.7% | ||
| Q2 25 | 2.5% | 53.6% | ||
| Q1 25 | -32.0% | 49.4% | ||
| Q4 24 | 9.1% | 170.6% | ||
| Q3 24 | — | 39.8% | ||
| Q2 24 | -4.2% | 51.3% | ||
| Q1 24 | -77.3% | 37.1% |
资本支出强度APLSCCB
| Q4 25 | 0.1% | 6.1% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.0% | 6.8% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 0.2% | 1.2% |
现金转化率APLSCCB
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 4.34× | ||
| Q2 25 | — | 5.99× | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.65× | ||
| Q2 24 | — | 6.22× | ||
| Q1 24 | — | 8.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
